EUNAE KIM

EUNAE KIM

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2014 in Apoptosis
Verified
Journal Article
Closed access
PDF file
EKEUNAE KIM
EUNAE KIM
JJJi-Hoon Jang
Ji-Hoon Jang
YLYun-Han Lee
Yun-Han Lee
ESEon-Gi Sung
Eon-Gi Sung
ISIn-Hwan Song
In-Hwan Song
TLTae-Jin Lee
Tae-Jin Lee

26 April 2017 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
JJJi Hoon Jang
Ji Hoon Jang
EKEUNAE KIM
EUNAE KIM
HPHye‐Jin Park
Hye‐Jin Park
ESEon‐Gi Sung
Eon‐Gi Sung
ISIn‐Hwan Song
In‐Hwan Song
TLTae-Jin Lee
Tae-Jin Lee
Methylglyoxal (MGO) is a reactive dicarbonyl metabolite of glucose, and its plasma levels are elevated in patients with diabetes. Studies have shown that MGO combines with the amino and sulphhydryl groups of proteins to form stable advanced glycation end products (AGEs), which are associated with vascular endothelial cell (EC) injury and may contribute to the progression of atherosclerosis. In this study, MGO induced apoptosis in a dose‐dependent manner in HUVECs, which was attenuated by pre‐treatment with z‐VAD, a pan caspase inhibitor. Treatment with MGO increased ROS levels, followed by dose‐dependent down‐regulation of c‐FLIPL. In addition, pre‐treatment with the ROS scavenger NAC prevented the MGO‐induced down‐regulation of p65 and c‐FLIPL, and the forced expression of c‐FLIPL attenuated MGO‐mediated apoptosis. Furthermore, MGO‐induced apoptotic cell death in endothelium isolated from mouse aortas. Finally, MGO was found to induce apoptosis by down‐regulating p65 expression at both the transcriptional and posttranslational levels, and thus, to inhibit c‐FLIPL mRNA expression by suppressing NF‐κB transcriptional activity. Collectively, this study showed that MGO‐induced apoptosis is dependent on c‐FLIPL down‐regulation via ROS‐mediated down‐regulation of p65 expression in endothelial cells.

3 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
EKEUNAE KIM
EUNAE KIM
SKSang-Woo Kim
Sang-Woo Kim
JNJehyun Nam
Jehyun Nam
ESEon-Gi Sung
Eon-Gi Sung
ISIn-Hwan Song
In-Hwan Song
TLTae-Jin Lee
Tae-Jin Lee
Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs

Verified
Journal Article
Open access
PDF file
SLSOO JUNG LEE
SOO JUNG LEE
JJJae-Hwan Jeong
Jae-Hwan Jeong
SLSoo Jung Lee
Soo Jung Lee
JKJieun Kang
Jieun Kang
EKEUNAE KIM
EUNAE KIM
YCYEE SOO Chae
YEE SOO Chae
MicroRNAs (miRNAs) can be used to target a variety of human malignancy by targeting their oncogenes or tumor suppressor genes. The developmental endothelial locus-1 (Del-1) might be under miRNA regulation. This study investigated microRNA-137 (miR-137) function and Del-1 expression in triple-negative breast cancer (TNBC) cells and tissues. Del-1 mRNA and miRNA-137 levels were determined via qRT-PCR in breast cancer cells (MDA-MB-231, MCF7, SK-BR3, and T-47D) and tissues from 30 patients with TNBC. The effects of miR-137 on cell proliferation, migration, and invasion were determined using MTT assays, wound healing, and Matrigel transwell assays. The luciferase reporter assay revealed direct binding of miR-137 to the 3′-UTR of Del-1. miR-137 inhibited cell proliferation, migration, and invasion of MDA-MB-231 cells. Among the 30 TNBC specimens, miR-137 was downregulated and Del-1 level in plasma was significantly elevated relative to normal controls. It is concluded that miR-137 regulates Del-1 expression in TNBC by directly binding to the Del-1 gene and cancer progression. The results implicate miR-137 as a new therapeutic biomarker for patients with TNBC.

1 June 2019 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
EKEUNAE KIM
EUNAE KIM
ESEon-Gi Sung
Eon-Gi Sung
ISIn-Hwan Song
In-Hwan Song
JKJoo-Young Kim
Joo-Young Kim
HSHwa-Jung Sung
Hwa-Jung Sung
TLTae-Jin Lee
Tae-Jin Lee
Neferine is an alkaloid extracted from a seed embryo of Nelumbo nucifera and has recently been shown to have anticancer effects in various human cancer cell lines. However, the detailed molecular mechanism of neferine-induced apoptosis has not been elucidated in renal cancer cells. In the present study, we observed that neferine induced inhibition of cell proliferation and apoptosis in Caki-1 cells in a dose-dependent manner by using MT assay and flow cytometry and that neferine-mediated apoptosis was attenuated by pretreatment with N-benzyloxycarbony-Val-Ala-Asp (O-methyl)-fluoromethyketone, a pan-caspase inhibitor. Treatments with neferine dose-dependently downregulated B cell lymphoma-2 (Bcl-2) expression at the transcriptional level determined by reverse transcriptase-polymerase chain reaction. The forced expression of Bcl-2 and p65 attenuated the neferine-mediated apoptosis in Caki-1 cells. In addition, neferine induced apoptosis by downregulating Bcl-2 and p65 expression in the other two kidney cancer cell lines determined by flow cytometry and western blot analysis. Finally, we observed that treatment with neferine induced apoptosis by inhibiting the NF-κB pathway through caspase-mediated cleavage of the p65 protein by western blot analysis. Collectively, this study demonstrated that neferine-induced apoptosis is mediated by the downregulation of Bcl-2 expression via repression of the NF-κB pathway in renal cancer cells.

17 January 2017 in International Journal of Oncology
Verified
Journal Article
Closed access
EKEUNAE KIM
EUNAE KIM
TKTae Ghab Kim
Tae Ghab Kim
ESEon-Gi Sung
Eon-Gi Sung
ISIn-Hwan Song
In-Hwan Song
JKJoo-Young Kim
Joo-Young Kim
TLTae-Jin Lee
Tae-Jin Lee
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications